These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method. Azar P; Nikoo M; Miles I Am J Addict; 2018 Dec; 27(8):601-604. PubMed ID: 30387894 [TBL] [Abstract][Full Text] [Related]
23. Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone. Kiyokawa M; Kwon AK; Cape MC; Streltzer JM Fam Pract; 2023 Nov; 40(4):596-598. PubMed ID: 37499179 [TBL] [Abstract][Full Text] [Related]
24. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887 [TBL] [Abstract][Full Text] [Related]
26. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251 [TBL] [Abstract][Full Text] [Related]
27. Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial. Zamani N; Buckley NA; Hassanian-Moghaddam H Crit Care; 2020 Feb; 24(1):44. PubMed ID: 32033582 [TBL] [Abstract][Full Text] [Related]
28. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence. Soyka M Expert Opin Drug Deliv; 2012 Nov; 9(11):1409-17. PubMed ID: 23013384 [TBL] [Abstract][Full Text] [Related]
29. A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic. Tofighi B; McNeely J; Walzer D; Fansiwala K; Demner A; Chaudhury CS; Subudhi I; Schatz D; Reed T; Krawczyk N J Addict Med; 2022 Jan-Feb 01; 16(1):e40-e43. PubMed ID: 33560696 [TBL] [Abstract][Full Text] [Related]
30. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence. Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329 [TBL] [Abstract][Full Text] [Related]
31. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. Barry DT; Moore BA; Pantalon MV; Chawarski MC; Sullivan LE; O'Connor PG; Schottenfeld RS; Fiellin DA J Gen Intern Med; 2007 Feb; 22(2):242-5. PubMed ID: 17356993 [TBL] [Abstract][Full Text] [Related]
33. Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: follow-up of a randomised trial. Bell JR; Ryan A; Mutch C; Batey R; Rea F Drug Alcohol Depend; 2008 Jul; 96(1-2):183-6. PubMed ID: 18423901 [TBL] [Abstract][Full Text] [Related]
34. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526 [TBL] [Abstract][Full Text] [Related]
35. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial. Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781 [TBL] [Abstract][Full Text] [Related]
36. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539 [TBL] [Abstract][Full Text] [Related]
37. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Correia CJ; Walsh SL; Bigelow GE; Strain EC Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637 [TBL] [Abstract][Full Text] [Related]
38. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder. Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944 [TBL] [Abstract][Full Text] [Related]
39. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Fiellin DA; Moore BA; Sullivan LE; Becker WC; Pantalon MV; Chawarski MC; Barry DT; O'Connor PG; Schottenfeld RS Am J Addict; 2008; 17(2):116-20. PubMed ID: 18393054 [TBL] [Abstract][Full Text] [Related]
40. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. O'Connor PG; Oliveto AH; Shi JM; Triffleman EG; Carroll KM; Kosten TR; Rounsaville BJ; Pakes JA; Schottenfeld RS Am J Med; 1998 Aug; 105(2):100-5. PubMed ID: 9727815 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]